A first-in-human trial shows that the conformation-selective PI3Kδ inhibitor roginolisib is well tolerated in advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results